思创医惠今日涨停，全天换手率20.58%，成交额12.09亿元，振幅20.34%。龙虎榜数据显示，机构净买 入237.35万元，营业部席位合计净买入9253.11万元。 融资融券数据显示，该股最新（1月12日）两融余额为1.70亿元，其中，融资余额为1.70亿元，融券余额 为26.58万元。近5日融资余额合计增加1407.95万元，增幅为9.06%，融券余额合计增加5.86万元，增幅 28.29%。（数据宝） 思创医惠1月13日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 开源证券股份有限公司西安西大街证券营业部 | 7178.09 | 46.36 | | 买二 | 东方证券股份有限公司杭州金鸡路证券营业部 | 4495.49 | 0.00 | | 买三 | 东方证券股份有限公司扬州文汇东路证券营业部 | 2360.21 | 0.00 | | 买四 | 华鑫证券有限责任公司上海虬江路证券营业部 | 2134.37 | 0.00 | | 买五 | 机构专用 | 2110.83 | 1968.58 | ...

市场分析认为，本轮行情核心驱动力在于产业趋势的明确确认。一方面，蚂蚁集团旗下的AI健康助 手"蚂蚁阿福"自发布后短期内月活用户突破3000万，单日提问量超千万，验证了健康AI赛道的巨大需求 和市场想象力。 与此同时，继"蚂蚁阿福"后，OpenAI于1月8日正式推出健康功能"ChatGPT Health"，标志着全球顶尖AI 公司一致看好并重仓健康AI赛道。市场观点指出，拥有成熟场景、与领先AI应用形成生态合作的医疗 健康公司，有望在此轮产业浪潮中持续受益。 今日，AI医疗与制药概念板块持续拉升，呈现井喷行情。板块内多只个股涨停，其中与"蚂蚁阿福"相关 的概念股成为绝对主线，表现最为强劲。华人健康、思创医惠收获"20厘米"涨停；美年健康、迪安诊断 双双录得连续第三个涨停板，卫宁健康等多只个股涨幅超过10%。 统计显示，自蚂蚁阿福2015年12月中旬面世以来，其生态辐射效应持续释放，相关概念股迎来重估。其 中，华人健康股价涨幅已接近翻倍，卫宁健康涨超80%，美年健康涨超50%。 ...

Core Viewpoint - The AI healthcare and pharmaceutical sectors are experiencing significant upward momentum, with multiple stocks reaching their daily limit up. Group 1: Stock Performance - Chinese Health (301408) and Sichuang Medical (300078) both hit the 20% daily limit up [1] - Other stocks such as Xin Ganjiang, Boji Pharmaceutical (300404), Nossger (301333), Puris (301257), and Dian Diagnostics (300244) also reached their daily limit up [1] - Companies like Okon Pharmaceutical, Rongchang Bio, Weining Health (300253), and BGI Genomics (300676) saw their stock prices increase by over 10% [1]

Core Viewpoint - The Shenzhen Stock Exchange has issued multiple penalties related to the convertible bond project of Sichuan Medical Technology Co., Ltd. (300078), highlighting issues of non-operational fund occupation and information disclosure violations by major shareholders and related parties [1] Group 1: Penalties and Disciplinary Actions - Sichuan Medical Technology and related parties received disciplinary actions from the Shenzhen Stock Exchange due to violations, including a public reprimand [1] - Citic Securities, the sponsor for the convertible bond project, and Tianjian Accounting Firm also received penalties, with their representatives facing similar disciplinary actions [1] - This marks the first instance of a securities company receiving a regulatory letter from the Shenzhen Stock Exchange since the implementation of the registration system in the ChiNext board [1] Group 2: Investigation Findings - Citic Securities failed to adequately address multiple inquiries from the Shenzhen Stock Exchange regarding fund occupation and prepayment issues, leading to the issuance of a false commitment letter [2] - From 2018 to 2020, the major shareholder, Hangzhou Sichuan Medical Technology Group Co., Ltd., and its affiliates occupied a total of 338.457 million yuan in funds, with a maximum daily balance of 200.5015 million yuan [2] - Although the occupied funds were returned by April 30, 2021, the Shenzhen Stock Exchange had previously requested Citic Securities to verify the existence of non-operational fund occupation [2] Group 3: Due Diligence Failures - Citic Securities conducted a series of misleading operations, failing to properly investigate the purpose and accounting treatment of prepayments and investments, despite being aware of significant anomalies [3][4] - The firm issued a commitment letter that inaccurately stated there were no fund occupations by major shareholders, contradicting the actual situation [3] - The Shenzhen Stock Exchange criticized Citic Securities for not following due diligence standards and for providing inaccurate verification opinions [4] Group 4: Audit Firm Responsibilities - Tianjian Accounting Firm, responsible for the annual audits and the convertible bond project, also faced scrutiny for not adequately identifying and assessing the risks of fund occupation [6] - The firm failed to maintain reasonable professional skepticism and did not verify the flow of funds despite clear indications of potential issues [6] - The Shenzhen Stock Exchange noted that Tianjian's audit measures were insufficient, primarily relying on contract reviews and management interviews without proper verification of fund flows [6] Group 5: Regulatory Environment - The issue of fund occupation has been a recurring topic in the sponsorship work, with recent regulatory revisions aimed at enhancing the quality of due diligence in securities issuance [7] - The new regulations emphasize the need for sponsors to investigate the reasons and rationality behind receivables from related parties, particularly concerning potential fund occupations [7] - Regulatory bodies have been intensifying quality control measures for various investment banking projects, indicating a stricter oversight environment [7]

Core Viewpoint - Sichuang Medical Technology Co., Ltd. is facing legal scrutiny for alleged fraudulent issuance of securities and violations of information disclosure, with the case now moving to prosecution stage [1][2][3]. Group 1: Legal Proceedings - The Hangzhou Public Security Bureau has concluded its investigation into Sichuang Medical, confirming clear criminal facts and sufficient evidence, and has transferred the case to the Hangzhou People's Procuratorate for prosecution [1]. - Sichuang Medical has received a notice from the Hangzhou Public Security Bureau requesting evidence related to the case, indicating ongoing legal processes [1]. Group 2: Company Operations - Despite the legal issues, Sichuang Medical claims that its production and operational activities are running normally and that the legal proceedings will not impact its business operations [2]. - The company is committed to cooperating with the legal authorities and aims to protect the legal rights of the company and its shareholders [2]. Group 3: Regulatory Actions - The Zhejiang Securities Regulatory Bureau has proposed administrative penalties against Sichuang Medical for fraudulent issuance and information disclosure violations, including a fine of 81.7 million yuan (approximately 8.17 million) for fraudulent fundraising [3][4]. - The regulatory body has also indicated that the former chairman and general manager, Zhang Lizhong, will face a 10-year market ban due to the severity of the violations [4]. Group 4: Financial Background - Sichuang Medical has raised a total of 3.028 billion yuan (approximately 302.8 million) through five fundraising activities, including an initial public offering and multiple private placements [4]. - The company’s initial public offering raised 986 million yuan (approximately 98.6 million), with net proceeds of 934.08 million yuan (approximately 93.4 million) after expenses [5].

Core Viewpoint - The company, Sichuang Medical Technology Co., Ltd., is facing legal scrutiny for alleged fraudulent issuance of securities and improper disclosure of important information, with the case now moving to the prosecution stage [3][4][5]. Group 1: Legal Proceedings - The company received a notice from the Hangzhou Public Security Bureau regarding the transfer of the case to the Hangzhou People's Procuratorate for prosecution, indicating that the investigation has concluded with clear criminal facts and sufficient evidence [4][5]. - The case originated from the company's public issuance of convertible bonds amounting to 817 million yuan in 2021, during which it allegedly fabricated financial data for 2019 and 2020 through fictitious business activities and inflated revenue [5][6]. - The actual controller, Zhang Lizhong, has been banned from the market due to his role in orchestrating the financial fraud, which included concealing related party fund usage [6][7]. Group 2: Company Operations and Strategy - Despite the ongoing legal issues, the company claims that its production and operational activities are running normally and that it will cooperate with the legal proceedings while protecting the rights of its shareholders [4][5]. - The company is undergoing a transformation focusing on compliance and core business, with plans to optimize its name and business scope to reflect its strategic direction in the Internet of Things sector [4][7]. - As of the third quarter of 2025, the company reported a revenue of 604 million yuan, a year-on-year increase of 7%, while reducing its net loss from 284 million yuan to 4.76 million yuan [7][8].

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]

格隆汇12月31日丨思创医惠(300078.SZ)公布，公司于2025年8月14日收到杭州市公安局出具给公司的 《调取证据通知书》【杭公（经）调证字[2025]00481号】，杭州市公安局侦办的公司等涉嫌欺诈发行 证券案需调取公司有关证据材料，具体内容详见公司2025年8月15日披露于巨潮资讯网的《关于收到杭 州市公安局调取证据通知书的公告》（公告编号：2025-087）。公司于近日收到杭州市公安局出具的 《移送审查起诉告知书》，《告知书》显示，公司等涉嫌欺诈发行证券，违规披露、不披露重要信息， 杭州市公安局已侦查终结，犯罪事实清楚，证据确实、充分，现将该案移送至杭州市人民检察院审查起 诉。 截至目前，公司各项生产经营活动保持正常有序运行。本次事项系前期涉案案件进入审查起诉阶段的正 常司法程序推进，公司将积极配合杭州市人民检察院的相关工作，依法维护公司及全体股东合法权益， 预计不会影响公司正常的生产经营。 ...

二、对公司的影响 证券代码：300078 证券简称：思创医惠 公告编号：2025-131 思创医惠科技股份有限公司 关于收到杭州市公安局《移送审查起诉告知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）于 2025 年 8 月 14 日收到 杭州市公安局出具给公司的《调取证据通知书》【杭公（经）调证字[2025]00481 号】，杭州市公安局侦办的公司等涉嫌欺诈发行证券案需调取公司有关证据材料， 具体内容详见公司 2025 年 8 月 15 日披露于巨潮资讯网（www.cninfo.com.cn，下 同）的《关于收到杭州市公安局调取证据通知书的公告》（公告编号：2025-087）。 公司于近日收到杭州市公安局出具的《移送审查起诉告知书》（杭公(经) 移审告字[2025]00471 号）（以下简称"《告知书》"），现将《告知书》的主 要内容公告如下： 一、《告知书》主要内容 《告知书》显示，公司等涉嫌欺诈发行证券，违规披露、不披露重要信息， 杭州市公安局已侦查终结，犯罪事实清楚，证据确实、充分，现将该案移送 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-130 思创医惠科技股份有限公司 关于完成工商登记变更并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）于 2025 年 12 月 3 日召开 第六届董事会第十四次会议审议通过了《关于选举第六届董事会董事长、代表公 司执行公司事务的董事的议案》；于 2025 年 12 月 12 日召开第六届董事会第十 五次会议、于 2025 年 12 月 29 日召开 2025 年第七次临时股东会审议通过了《关 于变更经营范围暨修订<公司章程>的议案》，具体内容详见公司在巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 公司已于近日办理完成上述工商变更登记手续，并取得了浙江省市场监督管 理局换发的《营业执照》，现将有关事项公告如下： 一、新取得营业执照的基本信息 统一社会信用代码：91330000754441902G 名称：思创医惠科技股份有限公司 注册资本：壹拾壹亿壹仟柒佰捌拾柒万贰仟贰佰叁拾元 类型：其他股份有限公司（上市） 成 ...